Nakamura Yasuhiko, Kamei Toshiaki, Shinagawa Masahiro, Sakamoto Yuka, Miwa Ichiro
Department of Gynecology, Yamaguchi Grand Medical Center, Yamaguchi, Japan.
J Obstet Gynaecol Res. 2015 May;41(5):809-12. doi: 10.1111/jog.12631. Epub 2014 Dec 16.
Primary ovarian squamous cell carcinoma is uncommon, and the optimal treatment strategy for this disease has not yet been established. A 71-year-old woman diagnosed with FIGO stage IIb pure ovarian squamous cell carcinoma underwent cytoreductive surgery followed by combination chemotherapy with paclitaxel and carboplatin. After the second treatment course, a recurrent mass grew rapidly, and serum tumor maker levels increased. Monotherapy with weekly irinotecan was then instituted. This second-line chemotherapy was remarkably effective, and the patient subsequently underwent complete interval debulking surgery with a pathological complete response after the third treatment course. Weekly irinotecan is an effective choice for primary ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin.
原发性卵巢鳞状细胞癌并不常见，且针对该疾病的最佳治疗策略尚未确立。一名71岁被诊断为国际妇产科联盟（FIGO）IIb期纯卵巢鳞状细胞癌的女性患者接受了肿瘤细胞减灭术，随后接受了紫杉醇和卡铂联合化疗。在第二个疗程后，复发肿块迅速增大，血清肿瘤标志物水平升高。随后采用每周一次的伊立替康单药治疗。这种二线化疗非常有效，患者随后在第三个疗程后接受了彻底的间隔期减瘤手术，术后病理显示完全缓解。对于对紫杉醇和卡铂联合化疗耐药的原发性卵巢鳞状细胞癌，每周一次的伊立替康是一种有效的选择。
